Immune checkpoint blockade therapy such as anti-PD-L1 is efficient for treating specific cancer types, but poor response rates remain a caveat. Here the authors generate a peptide-based, self-assembly nanomaterial that binds and aggregates PD-L1 as a fibrillar networks to enhance the anti-tumour efficacy of anti-PD-L1 in multiple mouse tumour models.
- Chunping Mao
- Fuan Deng
- Jun Shen
